Ventripoint Diagnostics Ltd. (VPTDF)
| Market Cap | 17.63M |
| Revenue (ttm) | 101.10K |
| Net Income (ttm) | -3.77M |
| Shares Out | n/a |
| EPS (ttm) | -0.02 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 20 |
| Average Volume | 15,234 |
| Open | 0.0998 |
| Previous Close | 0.1038 |
| Day's Range | 0.0995 - 0.1008 |
| 52-Week Range | 0.0497 - 0.2200 |
| Beta | 0.15 |
| RSI | 47.38 |
| Earnings Date | May 1, 2025 |
About Ventripoint Diagnostics
Ventripoint Diagnostics Ltd., a medical device company, engages in the development and commercialization of diagnostic tools that monitor patients with heart disease worldwide. It offers Ventripoint Medical System (VMS), a medical imaging system that is used to generate three-dimensional models with critical volume and functional measurements of a patient’s heart chambers. The company also provides VMS+ software, a 2D and 3D ultrasound models. In addition, it develops a suite of applications for various heart diseases and imaging modalities, in... [Read more]
Financial Performance
In 2023, Ventripoint Diagnostics's revenue was 49,183, a decrease of -27.85% compared to the previous year's 68,167. Losses were -4.87 million, -0.02% less than in 2022.
Financial numbers in CAD Financial StatementsNews
Ventripoint Provides Corporate Update and Announces Shareholder Teleconference
Toronto, Canada — April 10, 2025 — TheNewswire - Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company"), (TSXV:VPT; OTC:VPTDF) , a leading provider of innovative cardiac diagnostic solutions, i...
Ventripoint Appoints Nicolas Coutin to Oversee Clinical Affairs
Toronto, Ontario – TheNewswire - April 8, 2025 – Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company"), (TSXV:VPT; OTC:VPTDF) today announced that it has appointed Nic Coutin, PhD. to oversee ...
Ventripoint Makes Application to Amend Warrants
Toronto, Ontario, April 3, 2025 – TheNewswire - Ventripoint Diagnostics Ltd. (" Ventripoint " or the " Company "), (TSXV:VPT; OTC:VPTDF) announces that it has made an application to the TSX Venture E...
Ventripoint Diagnostics Publishes Whitepaper on the Use of AI in Whole-Heart Analysis
Toronto, Ontario – TheNewswire - March 24, 2025 - Ventripoint Diagnostics Ltd. (" Ventripoint " or the " Company "), (TSXV:VPT; OTC:VPTDF) is pleased to announce the release of a whitepaper comparing ...
Ventripoint Announces Closing of $500,000 Non-Brokered Convertible Debenture Unit Private Placement
Toronto, Ontario, March 21, 2025 – TheNewswire - Ventripoint Diagnostics Ltd. (“ Ventripoint ” or the “ Corporation ”, TSXV:VPT) announces the closing of its previously announced (see press release of...
Ventripoint Announces Non-Brokered Convertible Debenture Units Private Placement
Toronto, Ontario – TheNewswire - March 14, 2025 – Ventripoint Diagnostics Ltd. (“ Ventripoint ” or the “ Corporation ”) , ( TSXV:VPT) announces a non-brokered private placement of up to CDN$500,000 (...
Ventripoint Diagnostics Announces U.S. FDA 510(k) Clearance for VMS+(TM) 4.0 Automated Radiological Image Processing Software/System
Toronto, Ontario - TheNewswire - February 27, 2025 - Ventripoint Diagnostics Ltd. (" Ventripoint " or the " Company "), (TSXV:VPT; OTC:VPTDF) is pleased to announce that it has received U.S. Food and...
Ventripoint Issues Option Grants and Reports Exercise of Options
Toronto, Ontario – TheNewswire – February 11, 2024 - Ventripoint Diagnostics Ltd. (“ Ventripoint ” or the “ Corporation ”)(TSXV:VPT, OTC:VPTDF) announces that on January 20, 2025, the Corporation ...
Ventripoint Diagnostics issues shares for payment of debenture interest
Ventripoint Diagnostics issues shares to pay interest on convertible debentures, with shares priced at $0.11 subject to TSXV approval.